ZURA
Zura Bio Limited
Company Overview
| Mkt Cap | $249.04M | Price | $3.63 |
| Volume | 415.25K | Change | -1.09% |
| P/E Ratio | -4.8 | Open | $3.70 |
| Revenue | -- | Prev Close | $3.67 |
| Net Income | $-52.4M | 52W Range | $0.97 - $4.68 |
| Div Yield | N/A | Target | $13.33 |
| Overall | 55 | Value | 60 |
| Quality | -- | Technical | 50 |
No chart data available
About Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development; Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways; and Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33. Zura Bio Limited was founded in 2021 and is based in Henderson, Nevada.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ZURA | $3.63 | -1.1% | 415.25K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |